Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
When I bought my shares I contacted investorrelations@marstons.co.uk and received a reply of how to get the Privilege card for discounts.
When I bought my shares I contacted investorrelations@marstons.co.uk and received a reply of how to get the Privilege card for discounts.
In my last post I put "Pubs and Inns" , should have been "Inns and Taverns"
Very good service from Emily and Debbie.
Does the shareholder card discount drinks as well as food?
Just food in the "Pubs and Inns" managed houses and accommodation in the Hotels.
You need a minimum of 500 shares.
After you have the shares just contact investor relations at head office.
If the board get their way at the forthcoming meeting and do a consolidation and then double the shares in circulation how can the existing shareholders possible vote George off the board?
This should all be discussed at the same meeting with the SAG proposal first item on the agenda.
I bought my first shares in 2012, I have topped up more shares on many occasions since then. The last time in January was a serious attempt to average down when I thought a rise was coming. My current total value is less than my last top up.
I have read every RNS for the last 8 years and more than 90% of the posts on here, I still have no idea how many patients have been treated, how may are now cancer free or how many have got worse.
I used to look at the trial data regularly and the end date seems to get extended once a year.
I will not be putting another penny into this shambles
I think you have got the consolidation dates wrong, I posted this in December 2018. I did check the RNS's at the time but have not looked back to recheck.
"Val shares in issue.
22 April 15 Pre consolidation 3.7bn Post consolidation 30177214.
14 September 18 after share issue 531629383"
Happy to oblige.
Wild, Not sure whether you read advfn but if so hope you're well. Regarding dosing levels of Keytruda in the SCIB1 trial, when Keytruda was first approved by the FDA, the recommended dose was 2mg per kg of weight. This was changed to a fixed dose of 200mg regardless of weight in 2017 as pharmacokinetics data showed very little difference between the 2. So I don't think it's using a lower paediatric dose, just that Scancell have been using that slide for a long time and haven't updated it!! As far as I know Keytruda has been approved for paediatric use in a couple of cancers and for those they seem to have retained the weight based dose of 2mg per kg (makes sense) but I'm pretty sure it hasn't been approved for melanoma .
I cannot put more cash into my Shares ISA this year but a lot of my Scancell are in this ISA. How can I buy in the open offer, do I have to sell some Scancell shares and tail swallow, sell other shares within the ISA to raise the funds or can I just buy them outside of the ISA? Anyone else in the same situation?
Mine was paid in on Friday as well